Philip L McCarthy

Aug 30, 2024 | onclive.com | Philip L McCarthy

CommentaryVideoAugust 30, 2024Author(s):Fact checked by:Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

Jun 24, 2024 | onclive.com | Philip L McCarthy

Philip McCarthy, MD, director, the Blood and Marrow Transplant Program, Roswell Park Comprehensive Cancer Center, discusses findings from an investigation into neutrophils in the tumor microenvironment (TME) of multiple myeloma and their impact on progression-free survival (PFS).

Mar 29, 2024 | nature.com | Richard M. Higashi |Andrew Lane |Jianmin Wang |Philip L McCarthy

AbstractMyeloid derived suppressor cells (MDSCs) are key regulators of immune responses and correlate with poor outcomes in hematologic malignancies. Here, we identify that MDSC mitochondrial fitness controls the efficacy of doxorubicin chemotherapy in a preclinical lymphoma model.

Dec 17, 2023 | nature.com | Philip L McCarthy |Amin M. Alousi |David Miklos |Ran Reshef |Richard T Maziarz |John Levine

AbstractIdentifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to identify new biomarker models to predict aGvHD and overall mortality. Two new biomarkers (Gal-3 and LAG-3), and previously identified biomarkers (ST2/IL33R, IL6, Reg3A, PD-1, TIM-3, TNFR1) were screened.